Skip to main content
. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473

Figure 9.

Box plots compare the levels of ELISA IgG BAU/mL across different groups and vaccine doses at one month (A) and six months (B) post-vaccination. Groups include Healthy Control, Multiple Myeloma, Non-MM Hematological, and Solid, with doses ranging from two to four. Significant p-values are indicated. Measurements include geometric mean, 95% confidence interval, and sample sizes, shown separately for BNT162b2 and mRNA-1273 vaccines.

Anti-SARS-CoV-2 spike IgG levels post vaccination in serum samples from cancer and healthy cohorts within different vaccine groups. Comparison of serum anti-spike IgG levels in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts within different vaccine groups 1-month (A) and 6-months (B) post-vaccination. Anti-spike IgG levels were presented as Geometric Mean with 95% confidence intervals (95% CI). Box plots show median (horizontal bar), the first and third quartiles. Differences assessed by non-parametric Wilcoxon rank sum test. *p<0.05, **p<0.01, ****p<0.0001.